Asahi Kasei Pharma

The Asahi Kasei Group operates in the three business sectors of Material, Homes, and Health Care with $20B net revenue. In Healthcare segment, Asahi Kasei group has two pharmaceutical companies, named Asahi Kasei Pharma (AKP) and Veloxis. AKP is a mid-sized R&D-based Japanese company with strong presence in autoimmune, musculoskeletal, critical care and infectious diseases fields established through R&D and commercialization of our products, Teribone, Recomodulin, Kevzara, Plaquenil, Cresemba, etc. Veloxis is an US based company leading transplant area with an innovative product, Envarsus XR and ongoing development activities in that space. AKP and Veloxis have an ambition to become one global specialty pharma to serve for our patients in immunology and transplant-related areas. For our future growth and to achieve our mission, we are collaborating closely and actively looking for opportunities from early to late stage in-licensing with global rights as well as M&A.